Document is current

Any future updates will be listed below

NEPAD: Ocrelizumab punktet bei RRMS und PPMS

Crossref DOI link: https://doi.org/10.1007/s15202-017-1799-z

Published Online: 2017-09-01

Published Print: 2017-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark